Previous 10 | Next 10 |
2023-07-05 13:23:58 ET Shares of Amneal Pharmaceuticals (NYSE: AMRX) were down more than 13% as of 12:45 p.m. ET on Wednesday after the pharmaceutical company announced both positive and negative news regarding its clinical pipeline. The stock is still up more than 30% this year...
2023-07-05 10:02:39 ET Gainers: Impel Pharmaceuticals ( IMPL ) +32% . Adicet Bio ( ACET ) +18% . C4 Therapeutics ( CCCC ) +17% . NLS Pharmaceutics ( NLSP ) +7% . Poseida Therapeutics ( PSTX ) +4% . Losers: Amneal Pharmaceu...
2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...
2023-07-03 14:34:31 ET The US FDA has issued a Complete Response Letter to Amneal Pharmaceuticals ( NYSE: AMRX ) for Parkinson's disease candidate IPX203. The stock is down ~5% in after-hours trading Monday. The agency said that an adequate scientific bridge was not es...
- Launches authorized generic for Xyrem ® (sodium oxybate) in the U.S., representing another new complex generic product launch - Receives U.S. FDA approval for five new complex generics in the second quarter - Remains on track to deliver more than 30 new generic launch...
- Letter requests additional pharmacokinetic data - No clinical efficacy or manufacturing issues identified Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from t...
Newly Released Report Details Company’s Progress and Contributions Toward Good Health and Well-Being as a Leading Provider of Affordable Medicines Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its ...
- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma - Represents a high value, complex product launch for Amneal’s expanding injectable portfolio Amneal Pharmaceuticals, Inc. (N...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York City. Mr...
2023-05-18 12:07:41 ET Are you looking at the stock market today and preparing to identify the best penny stocks to buy now? If you are, you’re not alone. With the robust nature of bullish optimism this week, the “risk-on” trade is back for the time being. Fears...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...